AI Verdict
EW has stronger fundamentals based on our AI analysis.
EW vs REGN Fundamental Comparison
| Metric | EW | REGN |
|---|---|---|
| Revenue | $6.1B | $14.3B |
| Net Income | $1.1B | $4.5B |
| Net Margin | 17.7% | 31.4% |
| ROE | 10.4% | 14.4% |
| ROA | 7.8% | 11.1% |
| Current Ratio | 3.72x | 4.13x |
| Debt/Equity | 0.06x | 0.06x |
| EPS | $1.83 | $41.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
EW vs REGN: Frequently Asked Questions
Is EW or REGN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), EW has stronger fundamentals. EW is rated BUY (85% confidence) while REGN is rated BUY (80% confidence). This is not investment advice.
How does EW compare to REGN fundamentally?
Edwards Lifesciences Corp has ROE of 10.4% vs REGENERON PHARMACEUTICALS, INC.'s 14.4%. Net margins are 17.7% vs 31.4% respectively.
Which stock pays higher dividends, EW or REGN?
EW has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in EW or REGN for long term?
For long-term investing, consider that EW has BUY rating with 85% confidence, while REGN has BUY rating with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about EW vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For EW vs REGN, the AI consensus favors EW based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.